Insulet rolls out enhanced Omnipod 5 algorithm with Abbott sensor compatibility
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- US futures fall on tech selloff as concerns about hawkish Fed, AI spending mount
- SpaceX extends losses after $600 billion wipeout, tech stocks slide again
- Oil steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Insulet Announces U.S. Rollout of Enhanced Omnipod® 5 Algorithm and Expands Compatibility with Abbott’s FreeStyle Libre 3 Plus Sensor
June 3, 2026 7:00 AM EDTEnhanced algorithm with new 100 mg/dL Target Glucose and improved alarm handling helps users improve time in range and stay in Automated Mode longer Omnipod 5 is now compatible with Abbotts Libre 3 Plus sensor in U.S., giving users more choice in how they manage their diabetes New features are designed to improve outcomes, reduce diabetes burden, and unlock barriers to AID technology to meet the needs of people with diabetes
ACTON, Mass.--(BUSINESS WIRE)-- Insulet Corporation (NASDAQ:... More
